Therefore, conventional anti-diabetic drugs such as sulfonylureas are not suitable because of the risk of prolonged hypoglycemia in these patients [13]; recently approved DPP-4 inhibitors are used (with an appropriate dose reduction) in diabetes patients with severe renal impairment [14]. This evidence concerns the gene DPP4 and diabetes mellitus.